- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
Labcorp Holdings Inc.(LH)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for LH
11/20/2026: LH (3-star) is a STRONG-BUY. BUY for 21 days. Simulated Profits (11.61%). Updated daily EoD!
Labcorp Holdings Inc. is a leading global healthcare company operating at the intersection of clinical diagnostics and biopharmaceutical research. The company's primary strengths lie in its expansive nationwide testing network, diversified revenue streams, and essential role in routine and specialized medical care. Its central growth story centers on expanding high-margin oncology and genetic testing alongside strategic hospital laboratory partnerships. Key risks include pricing pressures from commercial payers, intense competition from rival operators, and labor cost inflation. The stock is best suited for value and defensive investors seeking stable healthcare exposure, with ongoing monitoring of reimbursement trends and hospital partnership execution required.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | Labcorp offers steady, predictable mid-single-digit organic growth rather than explosive technology-style expansion. |
| Momentum investor | Strong fit while signal remains positive | Momentum appeal depends on positive sector rotation into healthcare and favorable earnings surprises. |
| Value investor | Strong fit | The stock often trades at reasonable valuation multiples relative to its stable cash flows and defensive market position. |
| Dividend investor | Mixed fit | While the company pays a reliable dividend, its yield is modest compared to traditional high-yield income stocks. |
| Low-risk investor | Strong fit | As an essential healthcare provider with inelastic demand for diagnostics, it exhibits lower structural volatility than cyclical sectors. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Low | The stock generally experiences lower price volatility than high-growth tech or speculative sectors due to its defensive healthcare profile. |
| Valuation risk | Medium | Valuation compression can occur if broader market sentiment shifts away from defensive healthcare equities. |
| Competition risk (Quest Diagnostics and hospital labs) | Medium / high | Intense pricing rivalry with Quest Diagnostics and the growth of in-house hospital testing pose constant margin challenges. |
| Business quality | Strong | The company possesses entrenched network advantages, high barriers to entry, and essential status within the healthcare ecosystem. |
| Dividend income | Low | Dividend income is safe and supported by cash flow, but the total payout yield is relatively small for pure income seekers. |
| Execution risk | Medium | Integrating hospital laboratory acquisitions and managing large-scale operational labor workforces require continuous oversight. |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 29.81B USD | Price to earnings Ratio 30.09 | 1Y Target Price 390.06 |
Price to earnings Ratio 30.09 | 1Y Target Price 390.06 | ||
Volume (30-day avg) 729.4K shares | Beta 0.83 | 52 Weeks Range 243.20 - 375.10 | Updated Date 11/21/2026 |
52 Weeks Range 243.20 - 375.10 | Updated Date 11/21/2026 | ||
Dividends yield (FY) 0.78% | Basic EPS (TTM) 12.2 |
Sector & Industry Intelligence
Sector
Healthcare
Constructive- Sentiment
- Strong Bullish
- Momentum
- BUY Breadth Improving
- BUY participation
- 55.2%
- Active BUY / eligible
- 53 / 96
- 30-Day BUY Count Change
- +19
- Market state
- Strong Bullish
More qualifying stocks are receiving or maintaining BUY advisories, indicating improving market participation.
Industry
Diagnostics & Research
- BUY participation
- 14.3%
- Active BUY / eligible
- 1 / 7
- 30-Day BUY Count Change
- -4
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.

Smooth
The stock has moved along a generally orderly path with only modest fluctuations.
Analysis of Past Performance
Type Stock | Historic Profit 21.96% | Avg. Invested days 44 | Today’s Advisory Strong Buy |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Diagnostics | Routine testing, specialized genetic tests, oncology profiling, and wellness screens performed for physicians, hospitals, and direct consumers. | This is the core bread-and-butter testing business that generates steady, high-volume cash flow from everyday medical checkups. |
| Biopharma Laboratory Services | Central laboratory testing, biomarker discovery, and clinical trial support services provided to pharmaceutical and biotechnology companies. | This segment links Labcorp directly to global pharmaceutical innovation and drug development pipelines. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-10-28 | When Before Market | Estimate 4.65 | Actual 4.78 |
Profitability
Profit Margin 6.88% | Operating Margin (TTM) 11.18% |
Management Effectiveness
Return on Assets (TTM) 5.48% | Return on Equity (TTM) 11.44% |
Valuation
Trailing PE 30.09 | Forward PE 19.88 | Enterprise Value 36.47B | Price to Sales(TTM) 2.04 |
Enterprise Value 36.47B | Price to Sales(TTM) 2.04 | ||
Enterprise Value to Revenue 2.5 | Enterprise Value to EBITDA 16.86 | Shares Outstanding 81.20M | Shares Floating 80.81M |
Shares Outstanding 81.20M | Shares Floating 80.81M | ||
Percent Insiders 0.37 | Percent Institutions 100.33 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

